Skip to content
lifestyle.careersavvy.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Climb Bio, Inc.
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
October 2, 2026
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
September 3, 2026
Climb Bio to Present at Upcoming Investor Conferences
September 2, 2026
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
June 11, 2026
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
June 5, 2026
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
May 26, 2026
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
May 14, 2026
Climb Bio to Present at Upcoming Investor Conferences
May 12, 2026
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
1
2
Next Page
→